Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$1.49MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Leonard L. Mazur
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 1.00
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.04
Financials
Revenue
$1.49M-62.1%Net Income
$-8.86MEBITDA
$-9.97MFree Cash Flow
$-8.68MEPS (diluted)
$-0.34Shares Outstanding (diluted)
26.17M+10734.1%Operating Expenses
$11.01MCash & Debt
$17.01MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-37.43M | $-3.38 |
| 2024 | $0.00 | $-39.14M | $-5.97 |
| 2023 | $0.00 | $-32.54M | $-5.57 |
| 2022 | $0.00 | $-33.64M | $-5.75 |
| 2021 | $0.00 | $-23.05M | $-5.64 |
| 2020 | $0.00 | $-17.55M | $-11.20 |
| 2019 | $0.00 | $-15.58M | $-0.77 |
| 2018 | $0.00 | $-12.54M | $-1.17 |
| 2017 | $0.00 | $-10.38M | $-1.89 |
| 2016 | $0.00 | $-8.30M | $-2.29 |
| 2015 | $0.00 | $-2.90M | $-1.37 |
| 2014 | $0.00 | $-1.27M | $-0.95 |
| 2013 | $0.00 | $-31.4K | $-0.04 |
| 2012 | $0.00 | $-22.0K | $-0.03 |
Valuation
CTXRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
150+114.29%Social Signal Score
Mentions (3)
- Newsprnewswire.com·52d ago·Neutral
…ical affairs organizations deployed nationwide CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).
View source ↗ - Newsprnewswire.com·52d ago·Neutral
…the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal third quarter ended June 30, 2026, and provided a business update.
View source ↗ - Newsprnewswire.com·55d ago·Positive
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.
View source ↗
Earnings
Thu, Dec 17(in 2 months)
Consensus estimate $-0.41 per share
Typical surprise -38.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.34 vs $-0.36beat
- Fri, May 15$-0.95 vs $-0.28miss
- Fri, Feb 13$-0.38 vs $0.43miss
- Fri, Dec 26$-0.01 vs $-0.43beat
- Tue, Aug 12$-0.80 vs $-0.51miss
- Wed, May 14$-1.27 vs $-1.08miss
Estimates and results for CTXR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CTXR officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CTXR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.